

epigenomics

Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act):

Epigenomics signs joint commercialization agreement for Epi proColon® in North America with Polymedco

Berlin, Germany, October 01, 2013 – Epigenomics AG (ISIN: DE000A1K0516) announces that it has entered into a joint commercialization agreement with Polymedco Inc. Both companies will jointly commercialize Epi proColon®, Epigenomics' blood-based test for colorectal cancer (CRC) screening, in North America.

Under the terms of the agreement, Polymedco will deploy its CRC dedicated sales force and technical support staff, administration, logistics and other support functions to ensure the optimum market introduction and roll-out of Epi proColon® once the test is potentially approved by the US Food and Drug Administration. Both parties will work jointly on the marketing, launch and development strategies and with key payers to obtain favorable reimbursement coverage. Epigenomics will retain the responsibility to manufacture the product and to support it from the medical and regulatory point of view, including activities necessary to achieve inclusion in major cancer screening guidelines post approval. A working group comprised of representatives of both companies will oversee the launch and commercial roll-out and engage in activities necessary to ensure the commercial success of the product once it becomes available to the market. The companies agreed to a combined transfer price and profit sharing agreement subject to minimum annual sales of test kits from Epigenomics to Polymedco.

Polymedco is the largest provider of CRC screening tests in North America, with more than USD 50m in annual sales for its cancer diagnostics products and an established customer base of more than 1500 laboratories. The significant know-how and commitment of Polymedco to the CRC screening space will accelerate the commercial roll-out of Epi proColon® in North America and mean a significant time and resource advantage for Epigenomics between now and market launch of the product.

- End of Ad hoc -

Contact Epigenomics AG
Antje Zeise CIRO Manager IR PR Epigenomics AG Phone: +49 (0) 30 24345 386 ir@epigenomics.com www.epigenomics.com

Epigenomics' legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future

epigenomics

results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.